Safety explored in first-in-human study of KHK-4083, a monoclonal antibody targeting OX40 Sep. 29, 2017
Immune Pharmaceuticals gives update on phase II study of bertilimumab in severe bullous pemphigoid Sep. 28, 2017
RSS